GUTS Fractyl Health, Inc.
Price Chart
Executive Summary
Fractyl Health reported positive one-year open-label data from its REVEAL-1 Cohort, showing that patients who underwent a single Revita procedure maintained ~78% of prior GLP-1-induced weight loss at one year, with 33% continuing to lose weight. This compares favorably to published ~15% weight regain after GLP-1 withdrawal alone. The data supports Revita's potential as a durable, one-time procedural therapy for post-GLP-1 weight maintenance, with upcoming randomized readouts from REMAIN-1 Midpoint (Q3 2026) and Pivotal (early Q4 2026) cohorts as key catalysts.
Actionable Insight
The REVEAL-1 data de-risks Revita's post-GLP-1 weight maintenance thesis ahead of pivotal randomized readouts. Traders should monitor the REMAIN-1 Midpoint Cohort results in Q3 2026 and the REMAIN-1 Pivotal Cohort topline in early Q4 2026 as binary catalysts. The open-label nature and small sample (n=15) warrant caution, but the magnitude of weight maintenance vs. historical GLP-1 withdrawal data is compelling for an early-stage biotech.
Key Facts
- Participants retained ~78% of GLP-1-induced total body weight loss one year after a single Revita procedure (n=15).
- Mean total body weight change of 5.3% ± 2.1% at one year; 33% of patients continued to lose weight.
- Published third-party studies show ~15% weight regain after GLP-1 withdrawal alone at similar time points.
- No procedure-related serious adverse events; mild TEAEs in 36% of participants, transient and self-limited.
- Next catalysts: one-year randomized data from REMAIN-1 Midpoint Cohort in Q3 2026; topline six-month randomized data from REMAIN-1 Pivotal Cohort in early Q4 2026.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue. Positive data supports valuation re-rating potential for a $121M market cap biotech.
Risk Factors
- Open-label study design with small sample size (n=15 for efficacy) limits statistical reliability.
- Five participants withdrew or were lost to follow-up; two had protocol deviations, introducing potential bias.
- Upcoming randomized data (REMAIN-1) may not replicate open-label results; failure would significantly impair Revita's prospects.
- No revenue or near-term commercialization path; company relies on capital markets for funding.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306626 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Institutional Cluster
| $0.7265 awaiting T+1 | awaiting T+1 | — | $0.8500 (+17.00%) |
|
Jun 11, 2026
3d ago
|
Insider Cluster
| $0.7265 awaiting T+1 | awaiting T+1 | — | $0.8500 (+17.00%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $0.7200 awaiting T+1 | awaiting T+1 | — | $0.8500 (+18.06%) |
|
Jun 4, 2026
10d ago
|
8-K
| $0.7340 $0.6790 | ▼ −7.49% | ▼ −4.89% | $0.8500 (+15.80%) |
|
Jun 4, 2026
10d ago
|
Press Release
| $0.7340 $0.6790 | ▼ −7.49% | ▼ −4.89% | $0.8500 (+15.80%) |
|
May 12, 2026
4w ago
|
8-K
| $0.9480 $0.9480 | · 0.00% | ▲ +0.00% | $0.8500 (−10.34%) |
|
May 12, 2026
4w ago
|
Press Release
| $0.9480 $0.9480 | · 0.00% | ▲ +0.00% | $0.8500 (−10.34%) |
|
May 11, 2026
4w ago
|
8-K
| $0.7690 $0.7340 | ▼ −4.55% | ▼ −4.41% | $0.8500 (+10.53%) |
|
May 11, 2026
4w ago
|
Press Release
| $0.7690 $0.7340 | ▼ −4.55% | ▼ −4.41% | $0.8500 (+10.53%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $0.6530 $0.6560 | ▲ +0.46% | ▲ +0.94% | $0.8500 (+30.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access